about
Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease riskExploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3MDQC: a new quality assessment method for microarrays based on quality control reports.Proteomic signatures in plasma during early acute renal allograft rejectionWhite blood cell differentials enrich whole blood expression data in the context of acute cardiac allograft rejectionA computational pipeline for the development of multi-marker bio-signature panels and ensemble classifiers.Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic studyComputational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.Plasma protein biosignatures for detection of cardiac allograft vasculopathy.Alteration of human blood cell transcriptome in uremia.Variation in RNA-Seq transcriptome profiles of peripheral whole blood from healthy individuals with and without globin depletion.Two-stage, in silico deconvolution of the lymphocyte compartment of the peripheral whole blood transcriptome in the context of acute kidney allograft rejection.New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis.Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.Probability, predictors, and prognosis of posttransplantation glomerulonephritisEffects of sample timing and treatment on gene expression in early acute renal allograft rejection.Exploring phlebotomy technique as a pre-analytical factor in proteomic analyses by mass spectrometry.Eprodisate for the treatment of renal disease in AA amyloidosis.Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia.Proteomic biomarkers of recovered heart function.Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.Identifying HCV genotype 1 patients at risk of relapse.Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.Whole blood genomic biomarkers of acute cardiac allograft rejection.Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.Efficient panel designs for longitudinal recurrent event studies recording panel counts.Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines.A matched cohort pharmacoepidemiological analysis of steroid free immunosuppression in renal transplantation.Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.Patients in Australian Memory Clinics: baseline characteristics and predictors of decline at six months.Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes.Verification of a Proteomic Biomarker Panel to Diagnose Minor Stroke and Transient Ischaemic Attack: Phase 1 of SpecTRA, a Large Scale Translational Study.Novel Blood-based Transcriptional Biomarker Panels Predict the Late Phase Asthmatic Response.Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.Prevalence and predictors of burden in caregivers of people with dementia.Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Does executive impairment define a frontal variant of Alzheimer's disease?
P50
Q27330166-AA6AA6A3-A522-43A5-9F05-218D3834FBF2Q27485351-515DF26C-B17B-48A1-84B9-0EC8105C5F75Q33302482-BEEB35CE-16E9-47B4-AEDD-921B62C1C27AQ33587191-5FA3B757-1A9E-416C-8F60-12602ABE864DQ34253376-2623B1A7-F79D-4B91-BBB1-3BE4882D097AQ34502689-D1993CC3-116D-4C64-AF5D-5854468D00C5Q34589122-B99A922F-B910-4706-9D9F-06B461543F37Q34671668-394C97F2-48AB-4C76-A64B-A18A4EF070F9Q34782001-9FC65361-973F-43BE-A1DE-D2D3E5A4E5D7Q34786583-28CEB76D-0366-48FB-9EDF-BFBBED66CC1AQ35114464-B7D28815-3B8D-4835-AD4D-B0977533A3ADQ35148001-8A15B0D7-1419-40B2-9F58-3033CBD5E23CQ35691924-4B6978DB-5911-4507-BE7F-7E71F61EAC07Q35769129-B8E1308D-E16D-4A8E-888D-C5B29980D713Q37146427-FD1DFE2B-7FFC-4DCB-9E57-2436B1A95384Q38504226-ABD883B2-D85D-4D7A-98B1-41CFFE62D713Q40411051-66283231-295A-4068-99C3-9C9E2E87A48EQ40447968-EC004011-2A92-4366-9E13-B2D493469CB7Q41515631-0440A61E-C0A2-4F74-BB90-C863BB923180Q42226889-47369412-B466-464D-A474-F93B1400A304Q42977629-2C5C4849-71EC-493D-BDAE-BE0CD775BF13Q42995306-448CE48B-A75E-4D15-A0B7-F4CFD1B4339CQ43042004-068C1D51-3745-4AC1-9B12-E36B356A5FB9Q43283935-FFC4EE13-74D5-484F-952F-E9A91F211E6CQ44537550-C6BD772B-A95E-4AA2-92F2-940893097C55Q44971336-13BC6F63-8F73-43F0-88BA-819172732CD1Q45101921-1E196DBC-E797-40B4-8F54-348C0898004AQ45920993-5BF9E2D0-37C6-442F-BA40-1FA84165EBABQ46077970-1C6B44A3-8763-4AB0-8246-F1896BDB3D30Q46084217-9AB684E8-D59A-4760-BEA6-35082392731CQ46452813-95662E81-1C65-4D0F-9FED-BC5B27848DD6Q46531280-AEAE2F9E-0371-4934-A193-C7332EF8CC65Q46636683-CC1D1035-96B6-4AD1-8C01-9EF74F99F3E3Q46786059-C02BD257-6852-485E-A1D2-FD46D989095DQ47554120-3D01B5F2-FE0A-4944-9BDD-0CD54CFA041BQ47727545-AFC39E25-29FE-4C7E-91C5-37CB8BFE4382Q48687166-1C610AD5-3A0D-497A-89B2-9BD173C73CD7Q49065344-F7E249D6-A448-41E1-B85B-85FE7D123197Q50114703-411F0657-2494-4B20-92BC-1AF74F0210E7Q51842124-08DFAD2A-CAA1-48E9-BEF7-8D68F91DEE45
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert Balshaw
@ast
Robert Balshaw
@en
Robert Balshaw
@es
Robert Balshaw
@nl
Robert Balshaw
@sl
type
label
Robert Balshaw
@ast
Robert Balshaw
@en
Robert Balshaw
@es
Robert Balshaw
@nl
Robert Balshaw
@sl
altLabel
Rob Balshaw
@en
Robert F. Balshaw
@en
prefLabel
Robert Balshaw
@ast
Robert Balshaw
@en
Robert Balshaw
@es
Robert Balshaw
@nl
Robert Balshaw
@sl
P106
P1153
6602319443
P21
P31
P3835
robert-balshaw
P496
0000-0002-2455-8792